Additionally, YY2 overexpression decreased the resistance of HCC cells to cisplatin, an antitumor drug commonly used for treating patients with HCC, as indicated by a lower half‐inhibitory concentration (IC50; Figure S4E, Supporting Information). Here, YY2 is linked to hepatocellular carcinoma.